ACE Inhibitors Do NOT Inhibit Bradykinin—They Prevent Its Degradation
ACE inhibitors do not inhibit bradykinin; rather, they prevent the breakdown of bradykinin by blocking angiotensin-converting enzyme (ACE), which is the primary enzyme responsible for degrading bradykinin. This leads to accumulation of bradykinin in tissues, particularly in the upper respiratory tract, lungs, and vascular endothelium 1.
The Mechanism: ACE as a Dual-Function Enzyme
ACE serves two critical functions:
- Converts angiotensin I to angiotensin II (vasoconstrictor)
- Degrades bradykinin (also called kininase II)
When ACE is inhibited, both pathways are affected simultaneously. Importantly, ACE appears to have higher affinity for bradykinin than for angiotensin I, suggesting that ACE inhibitors may be more potent at preventing bradykinin degradation than at blocking angiotensin II production 2.
What Bradykinin Does: Physiological Effects
Bradykinin is a potent mediator with multiple beneficial and adverse effects:
Beneficial Cardiovascular Effects:
- Vasodilation: Acts on endothelial B2 receptors to cause endothelium-dependent vasodilation 3
- Blood pressure reduction: Contributes significantly to the antihypertensive effects of ACE inhibitors 4
- Natriuresis: Promotes sodium excretion
- Cardioprotection: Reduces oxidative stress, inflammation, and apoptosis 2
- Improved fibrinolysis: Enhances clot breakdown 2
Research demonstrates that bradykinin B2 receptor blockade attenuates the blood pressure-lowering effect of ACE inhibitors by approximately 50%, indicating that much of the therapeutic benefit comes from bradykinin accumulation rather than angiotensin II suppression 4.
Adverse Effects from Bradykinin Accumulation:
Dry cough (5-35% of patients):
- Bradykinin accumulates in the upper respiratory tract and lungs
- Acts as a protussive (cough-inducing) mediator
- Stimulates prostaglandin production, which further promotes cough
- Sensitizes airway sensory nerves 1
- More common in women, nonsmokers, and persons of Chinese origin 1
- Onset ranges from hours to months after starting therapy
- Resolution typically occurs 1-4 weeks after discontinuation, but may persist up to 3 months 1
Angioedema (0.1-0.7% of patients):
- Life-threatening when it affects head and neck
- Bradykinin-mediated tissue swelling
- Can occur even after prolonged use without prior episodes 5
Clinical Implications and Pitfalls
Key Caveat About ACE Inhibitor-Induced Cough:
In any patient with chronic cough taking an ACE inhibitor, consider the drug as causative regardless of how long they've been on it—even if they've tolerated it for years without problems 1. The temporal relationship between starting the medication and cough onset does NOT rule out ACE inhibitor causation.
Management Algorithm:
- For confirmed ACE inhibitor-induced cough: Discontinue the ACE inhibitor—this is the only uniformly effective treatment 1
- Switch to an angiotensin receptor blocker (ARB): ARBs do not affect bradykinin metabolism and have cough incidence similar to placebo 1
- If compelling reason to continue ACE inhibitor: After cough resolution, approximately 30% of patients will not develop cough upon rechallenge 1
The Bradykinin-Mediated Benefits Are Dose-Dependent:
Higher doses of ACE inhibitors provide greater cardioprotective benefits, likely through enhanced bradykinin signaling rather than further angiotensin II suppression 2. This explains why high-dose ACE inhibitor therapy shows superior outcomes in heart failure and post-MI patients.